I doubt they will announce the in vitro tests. Aft
Post# of 72440
(Total Views: 422)
Posted On: 03/30/2020 4:19:39 PM
I doubt they will announce the in vitro tests. After the in vitro trials they will structure clinical trials which will be announced.
A lot depends on the results of the current hydroxychloroquine Zithromax trial. If this cures everyone with no side effects it will impact the development of the other drugs.
The Ameican Academy of Ophthalmology recently issued an update regarding Hydroxychloroquine :
"The American Academy of Ophthalmology has no opinion on the use of chloroquine or hydroxychloroquine in COVID-19 patients. However, in a review of published guidelines for the use of these 2 drugs as treatment for COVID-19, a working group* from the Asia-Pacific Vitreo-retina Society found that proposed doses in many of the ongoing studies worldwide exceeded the maximum daily dose considered safe for long-term therapy (generally <5mg/kg of real weight for hydroxychloroquine) for rheumatic and other chronic diseases (WF Mieler, MD, personal communication, March 25, 2020).
The risk of irreversible maculopathy at these higher doses for short periods of time is unknown. Patients should be informed of the potential for macular toxicity before starting therapy. Furthermore, the need for baseline fundus examination and/or imaging is also unknown in cases with high doses over a relatively short duration..."
It seems there is concern for the 400mg bid dose which is the recommend dose by some. A small person say 120 lbs or 54 kg at 800mg/day dose is 14.8mg per day which greatly exceeds [ triples] the recommended dose. The short term risk seems poorly defined as patients at greatest risk for retinal damage and visual loss have been taking hydroxychloroquine for many years to control Rheumatic diseases such as Lupus and Rheumatoid arthritis.Pts with poor renal function have a much higher rate of visual toxicity from hydroxychloroquine.
So this concern about the potential for visual loss seems to open the door for alternative drugs like Brilacidin.
GLTA Farrell
A lot depends on the results of the current hydroxychloroquine Zithromax trial. If this cures everyone with no side effects it will impact the development of the other drugs.
The Ameican Academy of Ophthalmology recently issued an update regarding Hydroxychloroquine :
"The American Academy of Ophthalmology has no opinion on the use of chloroquine or hydroxychloroquine in COVID-19 patients. However, in a review of published guidelines for the use of these 2 drugs as treatment for COVID-19, a working group* from the Asia-Pacific Vitreo-retina Society found that proposed doses in many of the ongoing studies worldwide exceeded the maximum daily dose considered safe for long-term therapy (generally <5mg/kg of real weight for hydroxychloroquine) for rheumatic and other chronic diseases (WF Mieler, MD, personal communication, March 25, 2020).
The risk of irreversible maculopathy at these higher doses for short periods of time is unknown. Patients should be informed of the potential for macular toxicity before starting therapy. Furthermore, the need for baseline fundus examination and/or imaging is also unknown in cases with high doses over a relatively short duration..."
It seems there is concern for the 400mg bid dose which is the recommend dose by some. A small person say 120 lbs or 54 kg at 800mg/day dose is 14.8mg per day which greatly exceeds [ triples] the recommended dose. The short term risk seems poorly defined as patients at greatest risk for retinal damage and visual loss have been taking hydroxychloroquine for many years to control Rheumatic diseases such as Lupus and Rheumatoid arthritis.Pts with poor renal function have a much higher rate of visual toxicity from hydroxychloroquine.
So this concern about the potential for visual loss seems to open the door for alternative drugs like Brilacidin.
GLTA Farrell
(2)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼